Tissue Phenomics Blog

5B_Her2-classified.jpg

Posts by Topic

see all

Topics:  Immunotherapy, cancer immunotherapy, diagnostics, tissue phenomics, tissue biomarkers, tissue-based diagnostics, io-panel

The Power of Predictive Quantitative Tissue-Based Diagnostics in Cancer Immunotherapy

Nov 21, 2017 8:00:00 AM

The American Society of Clinical Oncology named Immunotherapy 2.0 “Advance of the Year” at its 2017 Annual Meeting in Chicago, IL. This recognition comes after decades of incremental progress in our understanding of how the human immune system interacts with cancerous lesions. It also is the culmination of recent successes with checkpoint inhibitor therapy that promised dramatic changes in clinical practice and the approach to cancer treatment. What started with cutaneous melanoma in 2011 is now rapidly showing remarkable results also in other
cancer types. Just over the past year, the Food and Drug Administration (FDA) approved the use of checkpoint inhibitors in five additional cancer indications: lung, head and neck, bladder, kidney, and classical Hodgkin lymphoma.

Read More

Topics:  precision medicine, cancer vaccines, personalized medicine, Immunotherapy, cancer diagnostics

Promising results with personalized cancer vaccines highlight the need for novel diagnostics to personalize cancer treatments

Aug 9, 2017 7:00:00 AM

Personalized medicine aims at bringing the right drug to the right patient at the right time. Getting many things right at the same time is challenging. There are many potential treatments for cancer patients and many of these can be combined with each other resulting in a lot of potential combination treatments. This growing number of treatment options makes it increasingly difficult to determine the right one for an individual patient. Biomarkers that help to predict response to a treatment are highly needed to guide treatment selection to maximize efficiency for both patients and payers.

Read More

Topics:  Immunotherapy, clinical trials, image analysis, predictive test, tumor microenvironment, oncology

Evaluation of the Tumor Microenvironment Using Image Analysis for Clinical Trials

May 8, 2017 7:30:00 AM

Advances in immunotherapy have dramatically changed the landscape for cancer researchers. With significant improvements in overall survival and recurrent free survival in some of the deadliest cancers, lives have been extended by years for some patients while other patients have not experienced benefit from immunotherapy treatment. For some cancer indications, such as non-small cell lung cancer, the FDA approved companion diagnostic test for PD-L1 by immunohistochemistry has predictive value on patient response. However, the test is not a perfect indicator of response as some PD-L1 negative patients will respond to therapy and, conversely, some PD-L1 positive patients will not. At the same time, the number of clinical trials examining immunotherapy and combination therapies with immunotherapy as a backbone has exceeded 1000 in 2017. The possibility of combination therapy brings many questions to light for the researcher and ultimately the physician on which therapy to choose, for how long, in what order and what potential combination. With these questions, comes the increasing need for predictive tests that can lead the physician to the right therapy at the right time.

Read More

Topics:  Immunotherapy, immuno-oncology, immunoscore, cancer therapy

The Top 3 Major Contributions to Immuno-oncology in 2016

Feb 6, 2017 8:29:57 AM

Immuno-oncology was a super-hot topic in 2016. Several thousand publications contributed to the scientific progress, so choosing the top 3 is a challenging undertaking. But there are a few common themes seen in many highly ranked publications: the use of the latest hard- and software to gain an improved mechanistic understanding, why immuno-oncology actually works, and guidance on how to both design and predict individual patient success of novel therapies.

Read More

Topics:  image analysis, real world evidence, tissue phenomics, Immunotherapy, immuno-oncology

Three reasons image analysis should be incorporated into your immunotherapy real-world evidence development strategy

Jan 9, 2017 5:00:00 AM

Clinical trials are extremely important to assess the safety and effectiveness of a new therapy or of a currently-available therapy in a new indication. However, there are a few drawbacks to clinical trials, such as:

Read More